Who are Dorzolamide-timolol and latanoprost's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dorzolamide-timolol-and-latanoprost.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dorzolamide-timolol and latanoprost — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dorzolamide-timolol and latanoprost (Dorzolamide-timolol and latanoprost) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog. Area: Ophthalmology.

marketed Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Dorzolamide-timolol and latanoprost (Dorzolamide-timolol and latanoprost) — Laboratorios Sophia S.A de C.V.. This combination reduces intraocular pressure through three mechanisms: dorzolamide inhibits carbonic anhydrase to decrease aqueous humor production, timolol blocks beta-adrenergic receptors to reduce aqueous humor secretion, and latanoprost increases uveoscleral outflow of aqueous humor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dorzolamide-timolol and latanoprost TARGET	Dorzolamide-timolol and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog	Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog class)

Laboratorios Sophia S.A de C.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dorzolamide-timolol and latanoprost — Competitive Intelligence Brief. https://druglandscape.com/ci/dorzolamide-timolol-and-latanoprost. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab